Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.

Oncotarget · 2014 · PMC4259439 · PMID 25238146

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The difference in median survival between mcr84 combined with low dose (32 days) and high dose (35 days) POL5551 did not reach statistical significance but there was an apparent difference in overall survival.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.